ArticleJournal of cachexia, sarcopenia and muscle2026
Brain-Derived Neurotrophic Factor, Sarcopenia and Digital Gait Characteristics in Older Adults: Insights Into the Brain-Muscle Axis.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBrain-derived neurotrophic factor (BDNF) is a core biomarker involved in the brain-muscle axis. This study aimed to investigate the associations of plasma BDNF with sarcopenia and multidimensional gait characteristics in older adults.
methodsWe enrolled 646 adults aged 60 years and older (mean age = 70.46 years; 56.97% females), among whom 65 (10.06%) were diagnosed with sarcopenia according to the Asian Working Group for Sarcopenia 2019. All participants underwent body composition analysis, comprehensive physical function assessments (handgrip strength, 6-m walk and five-time sit-to-stand test), and wearable sensor-based gait evaluation (including 14 parameters). Plasma levels of BDNF, along with multiple inflammatory and oxidative stress markers, were quantitatively measured. Multivariable regressions were conducted to examine the association of BDNF with sarcopenia and gait parameters, with adjustments for demographic characteristics, lifestyle factors, activities of daily living, cognitive function, depression and comorbidities.
resultsPlasma BDNF levels were significantly lower in older adults with sarcopenia compared to those without [1.82 (0.62, 4.95) μg/L versus 4.12 (0.81, 11.46) μg/L, p = 0.003]. BDNF was significantly correlated with appendicular skeletal muscle mass index (r = 0.11, p = 0.018), handgrip strength (r = 0.27, p < 0.001), gait speed (r = 0.32, p < 0.001) and sit-to-stand time (r = -0.34, p < 0.001). After full adjustment for covariates, the odds ratio (OR) for sarcopenia of ln-BDNF was 0.71 (95% CI: 0.63-0.81, p = 0.012). Ln-BDNF was negatively associated with swing time (β = -7.833, p = 0.011), step time (β = -12.769, p = 0.016), and stride time (β = -0.026, p = 0.012); and positively associated with thigh acceleration (β = 0.066, p = 0.001), thigh swing work (β = 0.039, p < 0.001), ground reaction force (β = 0.083, p < 0.001), foot landing control force (β = 0.224, p < 0.001), toe-off angle (β = 2.061, p < 0.001), step frequency (β = 1.615, p < 0.001) and stride length (β = 0.013, p < 0.001). Interleukin-6, interleukin-1β, superoxide dismutase and glutathione reductase were concurrently correlated with BDNF levels, sarcopenia status and gait parameters. Mediation analysis demonstrated that interleukin-1β mediated 14.65% of the relationship between BDNF and sarcopenia.
conclusionHigher BDNF levels are associated with a lower prevalence of sarcopenia and superior kinetic and spatiotemporal gait performance in older adults. Future experimental studies are needed to explore the potential mechanism by which BDNF regulates sarcopenia via neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.